What is new?
The original page explained the history of E. coli Nissle 1917 and its older evidence in ulcerative colitis. This update keeps that guide and adds a 2026 study of an engineered version designed to survive better in an inflamed colon.
Can Mutaflor help ulcerative colitis?
Older human trials suggest that the specific strain E. coli Nissle 1917 can help maintain remission in some people with ulcerative colitis. It does not reliably treat an active flare. The engineered version reported in 2026 was tested in mice and tissue models, not patients.
I am a consultant gastroenterologist, MBBS (London), FRCP (UK), with more than 25 years of clinical experience. When discussing probiotics, I look at the exact strain, purpose, disease activity and quality of evidence, not simply the word probiotic.
What is E. coli Nissle 1917?
E. coli is a large group of bacteria. Some strains can cause illness, while others do not. E. coli Nissle 1917, often shortened to EcN, is a non-pathogenic strain used as a probiotic for more than a century.
Mutaflor is one trade name associated with this strain. Product availability, regulation, formulation and approved uses vary between countries. A different probiotic labelled E. coli is not automatically the same strain and should not be assumed to have the same evidence.
What did the older ulcerative colitis trials show?
The best-known studies compared E. coli Nissle 1917 with mesalazine for maintaining remission. In a 12-month double-blind trial of 327 patients published in Gut, relapse occurred in 36.4% of evaluable patients assigned to E. coli Nissle and 33.9% assigned to mesalazine. The study was designed to test equivalence and supported E. coli Nissle as a possible maintenance alternative in selected circumstances.
An earlier randomised trial published in The Lancet also reported similar maintenance outcomes after remission had been achieved. These studies do not show that Mutaflor is superior to mesalazine, and the evidence does not cover every level of ulcerative colitis severity.
When might it be discussed?
The most reasonable discussion is maintenance of remission in a carefully selected patient, particularly when standard 5-ASA treatment is not tolerated or a patient has a strong preference after understanding the evidence.
The decision still depends on the extent and previous severity of ulcerative colitis, prior flares, objective inflammation, cancer-surveillance needs and what treatment achieved remission.
What changed in the 2026 study?
In a 2026 Gastroenterology study, researchers thought ordinary E. coli Nissle might struggle to establish itself in an inflamed bowel. They added a group of genes called the ttr operon. This allowed the engineered strain, EcN::ttr, to use tetrathionate, a substance produced in the inflamed intestine, as fuel.
In two mouse models of colitis, the engineered strain expanded during inflammation and reduced features of colitis more consistently than ordinary E. coli Nissle. The work also explored immune signalling, butyrate, bacterial movement across the barrier and barrier proteins. Human colonoids, laboratory-grown tissue models, were used for part of the barrier research. No patient with ulcerative colitis was treated.
| Evidence | What was studied | What we can say |
|---|---|---|
| Older human trials | Standard E. coli Nissle 1917 for maintenance | It may help maintain remission in selected patients |
| 2026 translational study | Engineered EcN::ttr in mice and human colonoids | The design is biologically interesting and needs human trials |
| Commercial Mutaflor | A product containing standard EcN 1917 | It is not the engineered research strain |
| Active ulcerative colitis | Limited and inconsistent probiotic evidence | Do not assume Mutaflor will control a flare |
Does the new study make Mutaflor more effective?
No. The study changed the bacterium genetically. Buying or taking standard Mutaflor does not provide EcN::ttr and cannot reproduce the experiment.
Before an engineered live bacterial treatment could enter routine care, human trials would need to assess dose, containment, safety, colonisation, shedding, medicine interactions and whether it improves symptoms and bowel healing.
Is Mutaflor the same as other probiotics?
No. Probiotic evidence is strain specific. Results for E. coli Nissle cannot be transferred to Lactobacillus, Bifidobacterium, a multi-strain product or another E. coli strain.
The clinical purpose also matters. Evidence for maintaining remission is not the same as evidence for treating active disease. A supplement may also vary in quality, storage and viable dose.
What should be checked before using it?
- Is the ulcerative colitis genuinely in remission?
- What treatment achieved remission, and what is the risk of relapse?
- Is this the exact E. coli Nissle 1917 strain and a regulated product?
- Could symptoms be from active inflammation, infection or another cause?
- How will response and inflammation be monitored?
Do not stop mesalazine, an immunosuppressant, a biologic or another prescribed treatment simply to try a probiotic.
What are the evidence limitations?
The main human maintenance trials are older, and treatment choices and monitoring have changed. Trial populations do not represent every patient. Availability and regulatory status differ between countries.
The 2026 study is proof of concept, not a patient trial. Benefits in mouse colitis and tissue models often do not translate directly to human ulcerative colitis.
Earlier Mutaflor overview
The 100-year-old probiotic
This preserves the original visual and video from the existing page. The earlier overview introduces E. coli Nissle 1917, its history and the maintenance evidence.
My clinical view
E. coli Nissle 1917 is one of the few probiotics with some clinical data behind it. It may be useful in selected circumstances, particularly for maintaining remission. I would not use it to manage an acute ulcerative colitis flare.
Would you like more evidence-based IBD updates?
Frequently asked questions
Is Mutaflor a medicine or a probiotic?
Mutaflor is a product containing the probiotic strain E. coli Nissle 1917. Its regulatory status and licensed indications vary by country.
Can Mutaflor treat an ulcerative colitis flare?
The stronger evidence is for maintenance of remission, not reliable control of an active flare. Bleeding, urgency or frequent diarrhoea needs assessment.
Is the engineered E. coli Nissle strain available to buy?
No. EcN::ttr was studied in laboratory and animal models. It is not the same as commercial Mutaflor and has not been proven in patients.
Can I stop mesalazine if I take Mutaflor?
Do not stop prescribed treatment without discussing the relapse risk and alternatives with the treating gastroenterologist or IBD team.
This page is for general education and does not replace individual medical advice. Probiotics can have risks and should not delay assessment of an ulcerative colitis flare.
Recommended related reading
If you would like to discuss ulcerative colitis maintenance treatment in your circumstances, you can use the appointment form below.